BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin.
BACKGROUND
In patients with type 2 diabetes mellitus (T2DM) with uncontrolled glycemia despite ongoing upward titration of basal insulin, targeting postprandial hyperglycemia may be required. Nevertheless, the point at which basal insulin is fully optimized and postprandial glucose (PPG) should be targeted with additional treatment remains unclear. We report here on the BeAM value (difference between bedtime and morning blood glucose values) as an indicator of the need to target PPG.


METHODS
This study had 3 stages: exploratory, main, and proof-of-concept analyses. For the exploratory and main analyses, data were pooled from phase 3 trials in adults with T2DM adding basal insulin to oral antidiabetic drugs (OADs). The main analysis included only patients who did not reach A1C ≤7.0% (53 mmol/mol) at week 24. The proof-of-concept analysis used pooled data from phase 3 trials in adults with T2DM adding insulin glargine and a single insulin glulisine injection to OADs.


RESULTS
In patients undergoing basal insulin titration, BeAM value increased over 24 weeks (27.8-61.7 mg/dL, n=1188; 32.6-71.2 mg/dL, n=553; exploratory and main analyses, respectively). There were significant correlations between week 24 BeAM value and postprandial contribution to hyperglycemia (Pearson's correlation coefficient (r)=0.375, p<0.001; r=0.396, p<0.001; exploratory and main analyses, respectively). When PPG was targeted (proof-of-concept analysis), the BeAM value reduced from 77.0 to 40.4 mg/dL (n=299).


CONCLUSIONS
The BeAM value described in this study is a simple, easy-to-calculate value that may identify patients with T2DM using basal insulin that need targeting of postprandial control rather than advancing basal insulin dose.
The Endocrine Center of Aventura , Aventura, Florida , USA.
Ariel
A
Zisman
Sanofi US, Inc. , Bridgewater, New Jersey , USA.
Francienid
F
Morales
Sanofi Canada , Laval, Quebec , Canada.
John
J
Stewart
Bayer Diabetes Care , Whippany, New Jersey , USA.
Andreas
A
Stuhr
Sanofi US, Inc. , Bridgewater, New Jersey , USA.
Aleksandra
A
Vlajnic
Medpace , Cincinnati, Ohio , USA.
Rong
R
Zhou
Insulin Adjustment; Insulin Treatment in Type 2 Diabetes; Postprandial Blood Glucose; Therapy Intervention